{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:51Z","timestamp":1786118931192,"version":"build-2736575974"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/wco.0b013e32830b0f61","type":"journal-article","created":{"date-parts":[[2008,9,3]],"date-time":"2008-09-03T07:04:35Z","timestamp":1220425475000},"page":"547-554","source":"Crossref","is-referenced-by-count":11,"title":["Plasma exchange in immune-mediated neuropathies"],"prefix":"10.1097","volume":"21","author":[{"given":"Helmar C","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Meyer zu H\u00f6rste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd C","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210206","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archneur.63.8.1066","article-title":"Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders","volume":"63","author":"Lehmann","year":"2006","journal-title":"Arch Neurol"},{"key":"R2-7-20210206","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1085-9489.2006.00061.x","article-title":"Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"11","author":"Hughes","year":"2006","journal-title":"J Peripher Nerv Syst"},{"key":"R3-7-20210206","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s001340050595","article-title":"Role of replacement fluids in the immediate complications of plasma exchange. French Registry Cooperative Group","volume":"24","author":"Korach","year":"1998","journal-title":"Intensive Care Med"},{"key":"R4-7-20210206","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ana.410220612","article-title":"Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids.","volume":"22","year":"1987","journal-title":"Ann Neurol"},{"key":"R5-7-20210206","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/jca.20142","article-title":"Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange","volume":"22","author":"Kankirawatana","year":"2007","journal-title":"J Clin Apher"},{"key":"R6-7-20210206","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"key":"R7-7-20210206","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.20076","article-title":"Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system","volume":"30","author":"Kieseier","year":"2004","journal-title":"Muscle Nerve"},{"key":"R8-7-20210206","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00019052-200110000-00008","article-title":"Progress in Guillain-Barr\u00e9 syndrome","volume":"14","author":"Hartung","year":"2001","journal-title":"Curr Opin Neurol"},{"key":"R9-7-20210206","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ana.20546","article-title":"Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome","volume":"58","author":"Halstead","year":"2005","journal-title":"Ann Neurol"},{"key":"R10-7-20210206","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/01.wco.0000173284.25581.2f","article-title":"Recent developments in Miller Fisher syndrome and related disorders","volume":"18","author":"Overell","year":"2005","journal-title":"Curr Opin Neurol"},{"key":"R11-7-20210206","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1085-9489.2005.0010202.x","article-title":"The immunobiology of Guillain-Barr\u00e9 syndromes","volume":"10","author":"Willison","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"R12-7-20210206","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410390105","article-title":"Pathology of the motor-sensory axonal Guillain-Barr\u00e9 syndrome","volume":"39","author":"Griffin","year":"1996","journal-title":"Ann Neurol"},{"key":"R13-7-20210206","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1749-6632.1998.tb09683.x","article-title":"Molecular mimicry in Guillain-Barr\u00e9 syndrome","volume":"845","author":"Sheikh","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"R14-7-20210206","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.0402391101","article-title":"Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barr\u00e9 syndrome","volume":"101","author":"Yuki","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-7-20210206","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.wco.0000174604.42272.2d","article-title":"Ganglioside mimicry as a cause of Guillain-Barr\u00e9 syndrome","volume":"18","author":"Yuki","year":"2005","journal-title":"Curr Opin Neurol"},{"key":"R16-7-20210206","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1523\/JNEUROSCI.4279-04.2005","article-title":"Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy","volume":"25","author":"Goodfellow","year":"2005","journal-title":"J Neurosci"},{"key":"R17-7-20210206","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/awh127","article-title":"Antiganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies","volume":"127","author":"Zhang","year":"2004","journal-title":"Brain"},{"key":"R18-7-20210206","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nbd.2007.07.008","article-title":"Antiganglioside antibodies alter presynaptic release and calcium influx","volume":"28","author":"Buchwald","year":"2007","journal-title":"Neurobiol Dis"},{"key":"R19-7-20210206","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1523\/JNEUROSCI.4401-06.2007","article-title":"Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers","volume":"27","author":"Susuki","year":"2007","journal-title":"J Neurosci"},{"key":"R20-7-20210206","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1523\/JNEUROSCI.4017-06.2007","article-title":"Passive immunization with antiganglioside antibodies directly inhibits axon regeneration in an animal model","volume":"27","author":"Lehmann","year":"2007","journal-title":"J Neurosci"},{"key":"R21-7-20210206","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"key":"R22-7-20210206","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ncpneuro0452","article-title":"From bench to bedside: experimental rationale for immune-specific therapies in the inflamed peripheral nerve","volume":"3","author":"Meyer zu Horste","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"R23-7-20210206","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0140-6736(84)91341-2","article-title":"Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy","volume":"1","author":"Greenwood","year":"1984","journal-title":"Lancet"},{"key":"R24-7-20210206","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(84)90819-5","article-title":"Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy","volume":"2","author":"Osterman","year":"1984","journal-title":"Lancet"},{"key":"R25-7-20210206","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/WNL.37.5.837","article-title":"Guillain-Barr\u00e9 syndrome: quantitative measurement of plasma exchange therapy","volume":"37","author":"Farkkila","year":"1987","journal-title":"Neurology"},{"key":"R26-7-20210206","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain-Barre syndrome.","volume":"35","year":"1985","journal-title":"Neurology"},{"key":"R27-7-20210206","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.410410304","article-title":"Appropriate number of plasma exchanges in Guillain-Barre syndrome.","volume":"41","year":"1997","journal-title":"Ann Neurol"},{"key":"R28-7-20210206","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1212\/WNL.51.3.875","article-title":"Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barr\u00e9 syndrome","volume":"51","author":"Yuki","year":"1998","journal-title":"Neurology"},{"key":"R29-7-20210206","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jca.20071","article-title":"The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barr\u00e9 syndrome","volume":"21","author":"Sanjay","year":"2006","journal-title":"J Clin Apher"},{"key":"R31-7-20210206","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"key":"R32-7-20210206","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.transci.2007.11.002","article-title":"Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study","volume":"38","author":"Kaynar","year":"2008","journal-title":"Transfus Apher Sci"},{"key":"R33-7-20210206","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.transci.2006.06.008","article-title":"Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases","volume":"36","author":"Yucesan","year":"2007","journal-title":"Transfus Apher Sci"},{"key":"R34-7-20210206","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. The Dutch Guillain-Barr\u00e9 Study Group","volume":"326","author":"van der Meche","year":"1992","journal-title":"N Engl J Med"},{"key":"R35-7-20210206","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R36-7-20210206","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1526-0968.2000.00183.x","article-title":"Immunoadsorption in Guillain-Barr\u00e9 syndrome and myasthenia gravis","volume":"4","author":"Haupt","year":"2000","journal-title":"Ther Apher"},{"key":"R37-7-20210206","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1526-0968.2004.00138.x","article-title":"Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barr\u00e9 syndrome","volume":"8","author":"Okamiya","year":"2004","journal-title":"Ther Apher Dial"},{"key":"R38-7-20210206","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.braindev.2004.09.013","article-title":"Immunoadsorption therapy for a child with Guillain-Barr\u00e9 syndrome subsequent to Mycoplasma infection: a case study","volume":"27","author":"Arakawa","year":"2005","journal-title":"Brain Dev"},{"key":"R39-7-20210206","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/brain\/awh083","article-title":"Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera","volume":"127","author":"Willison","year":"2004","journal-title":"Brain"},{"key":"R40-7-20210206","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1039\/B400029C","article-title":"Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barr\u00e9 syndrome","volume":"2","author":"Andersen","year":"2004","journal-title":"Org Biomol Chem"},{"key":"R41-7-20210206","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s001340051323","article-title":"Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barr\u00e9 syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome","volume":"26","author":"Esperou","year":"2000","journal-title":"Intensive Care Med"},{"key":"R42-7-20210206","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/(SICI)1098-1101(1999)14:3<107::AID-JCA1>3.0.CO;2-3","article-title":"Treatment of Guillain-Barr\u00e9 syndrome: a cost-effectiveness analysis","volume":"14","author":"Nagpal","year":"1999","journal-title":"J Clin Apher"},{"key":"R43-7-20210206","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jocn.2006.03.020","article-title":"Pharmacoeconomics of therapy for Guillain-Barr\u00e9 syndrome: plasma exchange and intravenous immunoglobulin","volume":"14","author":"Tsai","year":"2007","journal-title":"J Clin Neurosci"},{"key":"R44-7-20210206","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMra041347","article-title":"Chronic inflammatory demyelinating neuropathy","volume":"352","author":"Koller","year":"2005","journal-title":"N Engl J Med"},{"key":"R45-7-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-5728(96)00042-2","article-title":"Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathy","volume":"70","author":"Yuki","year":"1996","journal-title":"J Neuroimmunol"},{"key":"R46-7-20210206","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/brain\/awg030","article-title":"Autoimmunoreactivity to Schwann cells in patients with inflammatory neuropathies","volume":"126","author":"Kwa","year":"2003","journal-title":"Brain"},{"key":"R47-7-20210206","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1212\/WNL.59.12_suppl_6.S22","article-title":"Therapy of CIDP and related immune-mediated neuropathies","volume":"59","author":"Koski","year":"2002","journal-title":"Neurology"},{"key":"R48-7-20210206","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.60.8_suppl_3.S2","article-title":"The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents","volume":"60","author":"Toyka","year":"2003","journal-title":"Neurology"},{"key":"R49-7-20210206","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1471-4892(02)00158-3","article-title":"Immunosuppression in peripheral neuropathy: rationale and reality","volume":"2","author":"Sutton","year":"2002","journal-title":"Curr Opin Pharmacol"},{"key":"R50-7-20210206","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"N Engl J Med"},{"key":"R51-7-20210206","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"R52-7-20210206","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11882-007-0041-z","article-title":"Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"7","author":"Mehndiratta","year":"2007","journal-title":"Curr Allergy Asthma Rep"},{"key":"R54-7-20210206","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol"},{"key":"R55-7-20210206","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1468-1331.2006.01278.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society","volume":"13","author":"Hughes","year":"2006","journal-title":"Eur J Neurol"},{"key":"R56-7-20210206","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/jnnp.2004.056515","article-title":"Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"77","author":"Chan","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R57-7-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1085-9489.2006.00058.x","article-title":"Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.","volume":"11","year":"2006","journal-title":"J Peripher Nerv Syst"},{"key":"R58-7-20210206","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(05)70074-0","article-title":"Multifocal motor neuropathy","volume":"4","author":"Van Asseldonk","year":"2005","journal-title":"Lancet Neurol"},{"key":"R59-7-20210206","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0165-5728(01)00266-1","article-title":"Multifocal motor neuropathy","volume":"115","author":"Nobile-Orazio","year":"2001","journal-title":"J Neuroimmunol"},{"key":"R60-7-20210206","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"R61-7-20210206","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","article-title":"Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study","volume":"124","author":"L\u00e9ger","year":"2001","journal-title":"Brain"},{"key":"R62-7-20210206","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410240113","article-title":"A treatable multifocal motor neuropathy with antbodies to GM1 ganglioside","volume":"24","author":"Pestronk","year":"1988","journal-title":"Ann Neurol"},{"key":"R63-7-20210206","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jnnp.68.4.533","article-title":"Plasmapheresis in multifocal motor neuropathy: a case report","volume":"68","author":"Specht","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R65-7-20210206","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.1012","article-title":"Animal model of axonal Guillain-Barr\u00e9 syndrome induced by sensitization with GM1 ganglioside","volume":"49","author":"Yuki","year":"2001","journal-title":"Ann Neurol"},{"key":"R66-7-20210206","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00019052-200410000-00010","article-title":"IgM paraproteinaemic neuropathies","volume":"17","author":"Nobile-Orazio","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"R67-7-20210206","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1750-3639.2001.tb00407.x","article-title":"Paraproteinemic neuropathies","volume":"11","author":"Vital","year":"2001","journal-title":"Brain Pathol"},{"key":"R70-7-20210206","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1468-1331.2006.01467.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society","volume":"13","author":"Hadden","year":"2006","journal-title":"Eur J Neurol"},{"key":"R71-7-20210206","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199111213252105","article-title":"Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance","volume":"325","author":"Dyck","year":"1991","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WCO.0b013e32830b0f61","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:04:37Z","timestamp":1786035877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00019052-200810000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32830b0f61","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}